ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Matthew Siskin discussing real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Kevin Zarrabi discussing the molecular characterization of STEAP1 and STEAP2 in advanced prostate cancer. STEAP 1 and 2 ...

Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Brendan Raizenne presented Poster 4578: Prognostic utility ...

AURKA inhibitors might enhance outcomes of metastatic prostate cancer treated with androgen receptor pathway inhibitors by intensifying androgen receptor inhibition, increasing DNA-damage-related cell ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a New Frontiers in Prostate-Specific Membrane ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Stephen Freedland discussing treatment patterns and survival by race among men with metastatic ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ravi Madan discussing preliminary data from 6 month follow-up assessing prospective monitoring of PSMA–positive ...

Johnson & Johnson has nearly 20 years of leadership in prostate cancer, treating more than 750,000 patients worldwide. With the AMPLITUDE study, Johnson & Johnson becomes the first to show that a PARP ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Rana McKay discussing the molecular and clinical characterization of KLK2 mRNA expression in ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Prostate, ...